In the latest session, Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed at $1.40 up 6.06% from its previous closing price of $1.32. In other words, the price has increased by $+0.0800 from its previous closing price. On the day, 18675805 shares were traded. DNA stock price reached its highest trading level at $1.4200 during the session, while it also had its lowest trading level at $1.3100.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a deeper understanding of Ginkgo Bioworks Holdings Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.78 and its Current Ratio is at 6.78. In the meantime, Its Debt-to-Equity ratio is 0.32 whereas as Long-Term Debt/Eq ratio is at 0.32.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Raymond James on November 14, 2023, Downgraded its rating to Mkt Perform and sets its target price to $2.50 from $3.50 previously.
Goldman Downgraded its Neutral to Sell on June 02, 2023, whereas the target price for the stock was revised from $3 to $1.25.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 02 when Dmytruk Mark E. sold 39,569 shares for $1.21 per share. The transaction valued at 47,799 led to the insider holds 761,737 shares of the business.
Kelly Jason R sold 100,000 shares of DNA for $155,500 on Jan 04. The insider now owns 3,894,680 shares after completing the transaction at $1.55 per share. On Jan 03, another insider, Kelly Jason R, who serves as the insider of the company, sold 100,000 shares for $1.54 each. As a result, the insider received 154,400 and left with 3,994,680 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 2.99B. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.88 while its Price-to-Book (P/B) ratio in mrq is 2.07. Its current Enterprise Value per Revenue stands at 7.46 whereas that against EBITDA is -3.57.
Stock Price History:
Over the past 52 weeks, DNA has reached a high of $2.55, while it has fallen to a 52-week low of $1.12. The 50-Day Moving Average of the stock is 1.4312, while the 200-Day Moving Average is calculated to be 1.6631.
Shares Statistics:
For the past three months, DNA has traded an average of 21.30M shares per day and 21.72M over the past ten days. A total of 1.34B shares are outstanding, with a floating share count of 1.32B. Insiders hold about 34.10% of the company’s shares, while institutions hold 59.10% stake in the company. Shares short for DNA as of Jan 31, 2024 were 236.91M with a Short Ratio of 11.12, compared to 235.5M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 11.18% and a Short% of Float of 17.86%.
Earnings Estimates
There are 6 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.1 for the current quarter, with a high estimate of -$0.06 and a low estimate of -$0.14, while EPS last year was -$0.09. The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.06 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.41 and -$0.5 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.3, with 6 analysts recommending between -$0.22 and -$0.39.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $42.5M this quarter.It ranges from a high estimate of $56M to a low estimate of $36.8M. As of the current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $98.28M, an estimated decrease of -56.80% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $55.72M, a decrease of -31.00% over than the figure of -$56.80% in the same quarter last year. There is a high estimate of $64M for the next quarter, whereas the lowest estimate is $46.4M.
A total of 7 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $273M, while the lowest revenue estimate was $253.47M, resulting in an average revenue estimate of $258.72M. In the same quarter a year ago, actual revenue was $477.71M, down -45.80% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $279.55M in the next fiscal year. The high estimate is $325M and the low estimate is $233.03M. The average revenue growth estimate for next year is up 8.10% from the average revenue estimate for this year.
